ADC Therapeutics SA
ADCT
$3.10
-$0.01-0.32%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 77.25M | 75.82M | 70.84M | 70.72M | 66.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 77.25M | 75.82M | 70.84M | 70.72M | 66.75M |
| Cost of Revenue | 114.89M | 115.28M | 115.72M | 130.71M | 129.24M |
| Gross Profit | -37.65M | -39.46M | -44.89M | -60.00M | -62.49M |
| SG&A Expenses | 81.03M | 83.00M | 85.91M | 90.26M | 92.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 204.77M | 201.32M | 201.49M | 208.91M | 205.53M |
| Operating Income | -127.52M | -125.51M | -130.65M | -138.20M | -138.78M |
| Income Before Tax | -168.76M | -149.67M | -157.68M | -168.49M | -171.42M |
| Income Tax Expenses | 1.19M | 168.00K | 166.00K | 43.66M | 43.48M |
| Earnings from Continuing Operations | -169.94 | -149.84 | -157.85 | -212.15 | -214.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -169.94M | -149.84M | -157.85M | -212.15M | -214.91M |
| EBIT | -127.52M | -125.51M | -130.65M | -138.20M | -138.78M |
| EBITDA | -126.14M | -124.16M | -129.32M | -136.87M | -137.47M |
| EPS Basic | -1.57 | -1.45 | -1.66 | -2.40 | -2.55 |
| Normalized Basic EPS | -0.90 | -0.91 | -1.03 | -1.17 | -1.26 |
| EPS Diluted | -1.57 | -1.45 | -1.66 | -2.40 | -2.55 |
| Normalized Diluted EPS | -0.90 | -0.91 | -1.03 | -1.17 | -1.26 |
| Average Basic Shares Outstanding | 431.17M | 413.12M | 388.47M | 365.36M | 342.79M |
| Average Diluted Shares Outstanding | 431.17M | 413.12M | 388.47M | 365.36M | 342.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |